A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.

Trial Profile

A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Pazopanib (Primary) ; Diphenhydramine; Temsirolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
    • 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Mar 2016 Status changed from active, no longer recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top